{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:30:11Z","timestamp":1793701811773,"version":"4.5.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008977","name":"Universit\u00e4t Ulm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008977","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The hypothalamus as one of the core structures in metabolic control is increasingly recognized to be morphologically altered in various neurodegenerative diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this study was to quantitatively investigate the hypothalamic volumes in patients with progressive supranuclear palsy (PSP) and to compare them with controls and Parkinson disease (PD) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An automatic hypothalamic volume quantification method based on the use of convolutional neural networks (CNN) of U-Net architecture was applied to the automatic segmentation of the hypothalamus and intracranial volumes (ICV). This CNN-based volumetric analysis was performed in high resolution T1 weighted MRI in two PSP cohorts: cohort A with 78 PSP patients and 63 controls was recorded at 3.0\u00a0T at multiple sites; the single site cohort B consisted of 66 PSP patients, 66 PD patients, and 44 controls, recorded at 1.5\u00a0T.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In cohort A, significant hypothalamic volume reduction was observed in PSP (774\u2009\u00b1\u200983 mm\n                      <jats:sup>3<\/jats:sup>\n                      ) when compared to controls (817\u2009\u00b1\u200974 mm\n                      <jats:sup>3<\/jats:sup>\n                      ). In cohort B, this result of significant hypothalamic volume reduction was confirmed in PSP (745\u2009\u00b1\u2009102 mm\n                      <jats:sup>3<\/jats:sup>\n                      ) when compared to controls (831\u2009\u00b1\u200981 mm\n                      <jats:sup>3<\/jats:sup>\n                      ); no significant hypothalamic volume reduction was observed in PD (797\u2009\u00b1\u200998 mm\n                      <jats:sup>3<\/jats:sup>\n                      ), in support of previous studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The CNN-based hypothalamus volume quantification study demonstrated significantly reduced hypothalamus volumes in PSP patients compared to controls and PD, respectively; future studies will address the metabolic profiles of PSP as potential functional correlates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-13718-z","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:59:32Z","timestamp":1773241172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7106-9270","authenticated-orcid":false,"given":"Jan","family":"Kassubek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Z\u016fza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelia","family":"Kreiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Roselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the DESCRIBE-PSP Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Buerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emrah","family":"D\u00fczel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Falkenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Fl\u00f6el","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzel","family":"Glanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Janowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Katzdobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kilimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okka","family":"Kimmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Priller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Prudlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa-Sophie","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Spottke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike Jakob","family":"Spruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"13718_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2018.23","volume":"14","author":"RM Ahmed","year":"2018","unstructured":"Ahmed RM, Ke YD, Vucic S, Ittner LM, Seeley W, Hodges JR, Piguet O, Halliday G, Kiernan MC (2018) Physiological changes in neurodegeneration\u2014mechanistic insights and clinical utility. Nat Rev Neurol 14:259\u2013271. https:\/\/doi.org\/10.1038\/nrneurol.2018.23","journal-title":"Nat Rev Neurol"},{"key":"13718_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/B978-0-12-819973-2.00019-8","volume":"182","author":"RM Ahmed","year":"2021","unstructured":"Ahmed RM, Halliday G, Hodges JR (2021) Hypothalamic symptoms of frontotemporal dementia disorders. Handb Clin Neurol 182:269\u2013280. https:\/\/doi.org\/10.1016\/B978-0-12-819973-2.00019-8","journal-title":"Handb Clin Neurol"},{"key":"13718_CR3","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41598-025-85786-6","volume":"15","author":"J Kassubek","year":"2025","unstructured":"Kassubek J, Roselli F, Witzel S, Dorst J, Ludolph AC, Rasche V, Vernikouskaya I, M\u00fcller HP (2025) Hypothalamic atrophy in primary lateral sclerosis, assessed by convolutional neural network-based automatic segmentation. Sci Rep 15:1551. https:\/\/doi.org\/10.1038\/s41598-025-85786-6","journal-title":"Sci Rep"},{"key":"13718_CR4","doi-asserted-by":"publisher","first-page":"e209603","DOI":"10.1212\/WNL.0000000000209603","volume":"103","author":"A Michielsen","year":"2024","unstructured":"Michielsen A, van Veenhuijzen K, Janse van Mantgem MR, van Es MA, Veldink JH, van Eijk RPA, van den Berg LH, Westeneng HJ (2024) Association between hypothalamic volume and metabolism, cognition, and behavior in patients with amyotrophic lateral sclerosis. Neurology 103:e209603. https:\/\/doi.org\/10.1212\/WNL.0000000000209603","journal-title":"Neurology"},{"key":"13718_CR5","doi-asserted-by":"publisher","first-page":"109906","DOI":"10.1016\/j.compbiomed.2025.109906","volume":"189","author":"B Tafuri","year":"2025","unstructured":"Tafuri B, Giugno A, Nigro S, Zoccolella S, Barone R, Tamburrino L, Gnoni V, Urso D, Rollo E, De Blasi R, Logroscino G (2025) Radiomic alterations and clinical correlates of hypothalamic nuclei in ALS. Comput Biol Med 189:109906. https:\/\/doi.org\/10.1016\/j.compbiomed.2025.109906","journal-title":"Comput Biol Med"},{"key":"13718_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/B978-0-12-820107-7.00007-0","volume":"180","author":"CA Stewart","year":"2021","unstructured":"Stewart CA, Finger EC (2021) The supraoptic and paraventricular nuclei in healthy aging and neurodegeneration. Handb Clin Neurol 180:105\u2013123. https:\/\/doi.org\/10.1016\/B978-0-12-820107-7.00007-0","journal-title":"Handb Clin Neurol"},{"key":"13718_CR7","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s11548-025-03438-6","volume":"20","author":"I Vernikouskaya","year":"2025","unstructured":"Vernikouskaya I, Rasche V, Kassubek J, M\u00fcller HP (2025) Hypothalamus and intracranial volume segmentation at the group level by use of a Gradio-CNN framework. Int J Comput Assist Radiol Surg 20:1723\u20131731. https:\/\/doi.org\/10.1007\/s11548-025-03438-6","journal-title":"Int J Comput Assist Radiol Surg"},{"key":"13718_CR8","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/mds.27814","volume":"34","author":"M Gorges","year":"2019","unstructured":"Gorges M, Kuntz B, Del Tredici K, Schmidt DG, M\u00fcller HP, Ludolph AC, Dupuis L, Kassubek J (2019) Morphological MRI investigations of the hypothalamus in 232 individuals with Parkinson\u2019s disease. Mov Disord 34:1566\u20131570. https:\/\/doi.org\/10.1002\/mds.27814","journal-title":"Mov Disord"},{"key":"13718_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","volume":"140","author":"GG Kovacs","year":"2020","unstructured":"Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, Coughlin D, Giese A, Grossman M, Kurz C, McMillan CT, Gelpi E, Compta Y, van Swieten JC, Laat LD, Troakes C, Al-Sarraj S, Robinson JL, Roeber S, Xie SX, Lee VM, Trojanowski JQ, H\u00f6glinger GU (2020) Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol 140:99\u2013119. https:\/\/doi.org\/10.1007\/s00401-020-02158-2","journal-title":"Acta Neuropathol"},{"key":"13718_CR10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/mds.26973","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Sch\u00f6pe J, Stamelou M, Kassubek J, Del Ser T, Boxer AL, Wagenpfeil S, Huppertz HJ, AL-108-231 Investigators; Tauros MRI Investigators; Movement Disorder Society-Endorsed PSP Study Group (2017) Longitudinal magnetic resonance imaging in progressive supranuclear palsy: a new combined score for clinical trials. Mov Disord 32:842\u2013852. https:\/\/doi.org\/10.1002\/mds.26973","journal-title":"Mov Disord"},{"key":"13718_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70338","author":"PL Kukkle","year":"2025","unstructured":"Kukkle PL, Neupane R, Pantelyat A, Wills AM, Jabbari E, Dopper EGP, Kovacs GG, Hoglinger G, Aiba I, Litvan I, Ganguly J, Whitwell JL, Ma J, Okeng\u2019O K, Skakibara R, Forrest S, Lorenzl S, Zewde YZ, Compta Y, Morris HR, MDS\u2010PSP Study Group (2025) Progressive supranuclear palsy\u2014a global review. Mov Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70338","journal-title":"Mov Disord Clin Pract"},{"key":"13718_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/mds.27034","volume":"32","author":"G Respondek","year":"2017","unstructured":"Respondek G, Kurz C, Arzberger T et al (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 32:995\u20131005. https:\/\/doi.org\/10.1002\/mds.27034","journal-title":"Mov Disord"},{"key":"13718_CR13","doi-asserted-by":"publisher","first-page":"1569302","DOI":"10.3389\/fnagi.2025.1569302","volume":"17","author":"LA B\u00e2rlescu","year":"2025","unstructured":"B\u00e2rlescu LA, H\u00f6glinger GU, Volkmann H, Ludolph AC, Del Tredici K, Braak H, DESCRIBE-PSP Study Group, M\u00fcller HP, Kassubek J (2025) Diffusion tensor imaging of sequential neuropathological patterns in progressive supranuclear palsy. Front Aging Neurosci 17:1569302. https:\/\/doi.org\/10.3389\/fnagi.2025.1569302","journal-title":"Front Aging Neurosci"},{"key":"13718_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/mds.29866","volume":"39","author":"A Quattrone","year":"2024","unstructured":"Quattrone A, Franzmeier N, Huppertz H-J, Klietz M, Roemer SN, Boxer AL, Levin J, H\u00f6glinger GU, the AL-108-231 Investigators, the Tauros MRI Investigators, the PASSPORT Study Group, the DESCRIBE-PSP Group (2024) Magnetic resonance imaging measures to track atrophy progression in progressive supranuclear palsy in clinical trials. Mov Disord 39:1329\u20131342. https:\/\/doi.org\/10.1002\/mds.29866","journal-title":"Mov Disord"},{"key":"13718_CR15","doi-asserted-by":"publisher","first-page":"fcad048","DOI":"10.1093\/braincomms\/fcad048","volume":"5","author":"WJ Scotton","year":"2023","unstructured":"Scotton WJ, Shand C, Todd E, Bocchetta M, Cash DM, VandeVrede L, Heuer H, PROSPECT Consortium, 4RTNI Consortium, Young AL, Oxtoby N, Alexander DC, Rowe JB, Morris HR, Boxer AL, Rohrer JD, Wijeratne PA (2023) Uncovering spatiotemporal patterns of atrophy in progressive supranuclear palsy using unsupervised machine learning. Brain Commun 5:fcad048. https:\/\/doi.org\/10.1093\/braincomms\/fcad048","journal-title":"Brain Commun"},{"key":"13718_CR16","doi-asserted-by":"publisher","first-page":"fcac098","DOI":"10.1093\/braincomms\/fcac098","volume":"4","author":"WJ Scotton","year":"2022","unstructured":"Scotton WJ, Bocchetta M, Todd E, Cash DM, Oxtoby N, VandeVrede L, Heuer H, PROSPECT Consortium, 4RTNI Consortium, Alexander DC, Rowe JB, Morris HR, Boxer A, Rohrer JD, Wijeratne PA (2022) A data-driven model of brain volume changes in progressive supranuclear palsy. Brain Commun 4:fcac098. https:\/\/doi.org\/10.1093\/braincomms\/fcac098","journal-title":"Brain Commun"},{"key":"13718_CR17","doi-asserted-by":"publisher","first-page":"fcae055","DOI":"10.1093\/braincomms\/fcae055","volume":"6","author":"V Planche","year":"2024","unstructured":"Planche V, Mansencal B, Manjon JV, Meissner WG, Tourdias T, Coup\u00e9 P (2024) Staging of progressive supranuclear palsy-Richardson syndrome using MRI brain charts for the human lifespan. Brain Commun 6:fcae055. https:\/\/doi.org\/10.1093\/braincomms\/fcae055","journal-title":"Brain Commun"},{"key":"13718_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853\u2013864. https:\/\/doi.org\/10.1002\/mds.26987","journal-title":"Mov Disord"},{"key":"13718_CR19","doi-asserted-by":"publisher","first-page":"N99","DOI":"10.1088\/0031-9155\/52\/6\/N01","volume":"52","author":"HP M\u00fcller","year":"2007","unstructured":"M\u00fcller HP, Unrath A, Ludolph AC, Kassubek J (2007) Preservation of diffusion tensor properties during spatial normalization by use of tensor imaging and fibre tracking on a normal brain database. Phys Med Biol 52:N99\u2013N109. https:\/\/doi.org\/10.1088\/0031-9155\/52\/6\/N01","journal-title":"Phys Med Biol"},{"key":"13718_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaneurol.2025.011","volume":"82","author":"DE Vaillancourt","year":"2025","unstructured":"Vaillancourt DE, Barmpoutis A, Wu SS et al (2025) Automated imaging differentiation for Parkinsonism. JAMA Neurol 82:495\u2013505. https:\/\/doi.org\/10.1001\/jamaneurol.2025.011","journal-title":"JAMA Neurol"},{"key":"13718_CR21","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaneurol.2018.0640","volume":"75","author":"E De Pablo-Fern\u00e1ndez","year":"2018","unstructured":"De Pablo-Fern\u00e1ndez E, Courtney R, Warner TT, Holton JL (2018) A Histologic study of the circadian system in Parkinson disease, multiple system atrophy, and progressive supranuclear palsy. JAMA Neurol 75:1008\u20131012. https:\/\/doi.org\/10.1001\/jamaneurol.2018.0640","journal-title":"JAMA Neurol"},{"key":"13718_CR22","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1007\/s10072-024-07533-5","volume":"45","author":"MF Tepedino","year":"2024","unstructured":"Tepedino MF, Avallone AR, Abate F, Serio M, Caterino M, Erro R, Pellecchia MT, Barone P, Picillo M (2024) Longitudinal change of energy expenditure, body composition and dietary habits in Progressive Supranuclear Palsy patients. Neurol Sci 45:4335\u20134340. https:\/\/doi.org\/10.1007\/s10072-024-07533-5","journal-title":"Neurol Sci"},{"key":"13718_CR23","doi-asserted-by":"publisher","first-page":"984317","DOI":"10.3389\/fnmol.2022.984317","volume":"15","author":"S Bergh","year":"2022","unstructured":"Bergh S, Cheong RY, Peters\u00e9n \u00c5, Gabery S (2022) Oxytocin in Huntington\u2019s disease and the spectrum of amyotrophic lateral sclerosis-frontotemporal dementia. Front Mol Neurosci 15:984317. https:\/\/doi.org\/10.3389\/fnmol.2022.984317","journal-title":"Front Mol Neurosci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13718-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13718-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13718-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:09:28Z","timestamp":1774516168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13718-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["13718"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13718-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has any potential conflicts of interest for this manuscript. All authors exclude financial support for this study. G\u00fcnter H\u00f6glinger has ongoing research collaborations with Roche, UCB, and Abbvie; serves as a consultant for Abbvie, Alzprotect, Amylyx, Aprinoia, Asceneuron, Bayer, Bial, Biogen, Biohaven, Epidarex, Ferrer, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, Servier, Takeda, Teva, and UCB; received honoraria for scientific presentations from Abbvie, Bayer, Bial, Biogen, Bristol Myers Squibb, Esteve, Kyowa Kirin, Pfizer, Roche, Teva, UCB, and Zambon; holds a patent \u201cTreatment of Synucleinopathies\u201d US Patent No.: US 10,918,628 B2\/European Patent Patent No.: EP 17 787 904.6-1109\/3 525 788; received publication royalties from Academic Press, Kohlhammer, and Thieme. G\u00fcnter H\u00f6glinger was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany\u2019s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy\u2014ID 390857198); European Joint Programme on Rare Diseases (Improve-PSP); Petermax-M\u00fcller Foundation (Etiology and Therapy of Synucleinopathies and Tauopathies). Jan Kassubek has received honoraria or consultation fees from AbbVie, Bial, Biogen, Desitin, Esteve, Licher MT, Medtronic, NeuroDerm, Novartis, STADA, UCB Pharma, and Zambon; in addition, he is Specialty Chief Editor for Frontiers in Neurology (section Applied Neuroimaging) and Associate Editor (Neurology) for Therapeutic Advances in Chronic Disease.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"201"}}